Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care |
journalArticle |
2015 |
Schneider, D.; Bianchini, G.; Horgan, D.; Michiels, S.; Witjes, W.; Hills, R.; Plun-Favreau, J.; Brand, A.; Lawler, M. |
Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives |
journalArticle |
2015 |
Mirghani, H.; Amen, F.; Blanchard, P.; Moreau, F.; Guigay, J.; Hartl, D. M.; Lacau St Guily, J. |
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review |
journalArticle |
2015 |
Chouaïd, C.; Crequit, P.; Borget, I.; Vergnenegre, A. |
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer |
journalArticle |
2019 |
Le Rhun, E.; Wallet, J.; Mailliez, A.; Le Deley, M. C.; Rodrigues, I.; Boulanger, T.; Lorgis, V.; Barriere, J.; Robin, Y. M.; Weller, M.; Bonneterre, J. |
[Editorial] |
journalArticle |
2018 |
Perrier, L. |
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |
How individual participant data meta-analyses have influenced trial design, conduct, and analysis |
journalArticle |
2015 |
Tierney, J. F.; Pignon, J. P.; Gueffyier, F.; Clarke, M.; Askie, L.; Vale, C. L.; Burdett, S.; Cochrane, I. P. D. Meta-analysis Methods Group |
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma |
journalArticle |
2015 |
Izzedine, H.; Derosa, L.; Le Teuff, G.; Albiges, L.; Escudier, B. |
Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al |
journalArticle |
2015 |
de Baère, T.; Aupérin, A.; Deschamps, F.; Chevallier, P.; Gaubert, Y.; Boige, V.; Fonck, M.; Escudier, B.; Palussiére, J. |
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type |
journalArticle |
2018 |
Beylot-Barry, M.; Mermin, D.; Maillard, A.; Bouabdallah, R.; Bonnet, N.; Duval-Modeste, A. B.; Mortier, L.; Ingen-Housz-Oro, S.; Ram-Wolff, C.; Barete, S.; Dalle, S.; Maubec, E.; Quereux, G.; Templier, I.; Bagot, M.; Grange, F.; Joly, P.; Vergier, B.; Vially, P. J.; Gros, A.; Pham-Ledard, A.; Frison, E.; Merlio, J. P. |
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group |
journalArticle |
2016 |
Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C. |
Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life |
journalArticle |
2020 |
M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget |
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door |
journalArticle |
2018 |
Verlingue, L.; Hollebecque, A.; Lacroix, L.; Postel-Vinay, S.; Varga, A.; El Dakdouki, Y.; Baldini, C.; Balheda, R.; Gazzah, A.; Michot, J. M.; Marabelle, A.; Mir, O.; Arnedos, M.; Rouleau, E.; Solary, E.; De Baere, T.; Angevin, E.; Armand, J. P.; Michiels, S.; André, F.; Deutsch, E.; Scoazec, J. Y.; Soria, J. C.; Massard, C. |
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2017 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours |
journalArticle |
2016 |
Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K. |
How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models |
journalArticle |
2015 |
Minacori, R.; Bonastre, J.; Lueza, B.; Marguet, S.; Levy, P. |
Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study |
journalArticle |
2015 |
Jourdain, A.; Auperin, A.; Minard-Colin, V.; Aladjidi, N.; Zsiros, J.; Coze, C.; Gandemer, V.; Bertrand, Y.; Leverger, G.; Bergeron, C.; Michon, J.; Patte, C. |
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer |
journalArticle |
2016 |
Lamartina, L.; Ippolito, S.; Danis, M.; Bidault, F.; Borget, I.; Berdelou, A.; Al Ghuzlan, A.; Hartl, D.; Blanchard, P.; Terroir, M.; Deandreis, D.; Schlumberger, M.; Baudin, E.; Leboulleux, S. |
Phase I–II trial designs: how early should efficacy guide the dose recommendation process? |
journalArticle |
2018 |
Paoletti, X; Postel-Vinay, S |
Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis |
journalArticle |
2016 |
Lueza, B.; Rotolo, F.; Bonastre, J.; Pignon, J. P.; Michiels, S. |
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial |
journalArticle |
2015 |
Salgado, R.; Denkert, C.; Campbell, C.; Savas, P.; Nuciforo, P.; Aura, C.; de Azambuja, E.; Eidtmann, H.; Ellis, C. E.; Baselga, J.; Piccart-Gebhart, M. J.; Michiels, S.; Bradbury, I.; Sotiriou, C.; Loi, S. |
Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking? |
journalArticle |
2018 |
Bibault, J. E.; Blanchard, P. |
MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity |
journalArticle |
2016 |
Petit, C.; Dumas, I.; Chargari, C.; Martinetti, F.; Maroun, P.; Doyeux, K.; Tailleur, A.; Haie-Meder, C.; Mazeron, R. |
Daily Biopsy Diagnosis in Surgical Pathology: Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions |
journalArticle |
2018 |
Villa, I.; Mathieu, M. C.; Bosq, J.; Auperin, A.; Pomerol, J. F.; Lacroix-Triki, M.; Scoazec, J. Y.; Dartigues, P. |
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience |
journalArticle |
2016 |
Bluthgen, M. V.; Boutros, C.; Fayard, F.; Remon, J.; Planchard, D.; Besse, B. |
Revisiting vascular contraindications for transoral robotic surgery for oropharyngeal cancer |
journalArticle |
2018 |
Gorphe, P.; Auperin, A.; Honart, J. F.; Ton Van, J.; El Bedoui, S.; Bidault, F.; Temam, S.; Kolb, F.; Qassemyar, Q. |
[Network meta-analyses: Interest and limits in oncology] |
journalArticle |
2016 |
Ribassin-Majed, L.; Pignon, J. P.; Michiels, S.; Blanchard, P. |
Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival |
journalArticle |
2015 |
Kapetanakis, N. I.; Uzan, C.; Jimenez-Pailhes, A. S.; Gouy, S.; Bentivegna, E.; Morice, P.; Caron, O.; Gourzones-Dmitriev, C.; Le Teuff, G.; Busson, P. |
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas |
journalArticle |
2018 |
Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J. Y.; Malka, D.; Paci, A.; Hollebecque, A. |
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
[Reirradiation for head and neck squamous cell carcinoma: Indications and results] |
journalArticle |
2019 |
Biau, J.; Moreau, J.; Blanchard, P.; Thariat, J.; Miroir, J.; Lapeyre, M. |
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? |
journalArticle |
2016 |
Ducreux, M.; Pignon, J. P. |
[Economic analysis of multinational clinical trials in oncology] |
journalArticle |
2018 |
Lejeune, C.; Lueza, B.; Bonastre, J. |
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study |
journalArticle |
2017 |
Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S. |
Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review |
journalArticle |
2016 |
Gault, N.; Castaneda-Sanabria, J.; Guillo, S.; Foulon, S.; Tubach, F. |
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status |
journalArticle |
2015 |
Messai, Y.; Gad, S.; Noman, M. Z.; Le Teuff, G.; Couve, S.; Janji, B.; Kammerer, S. F.; Rioux-Leclerc, N.; Hasmim, M.; Ferlicot, S.; Baud, V.; Mejean, A.; Mole, D. R.; Richard, S.; Eggermont, A. M.; Albiges, L.; Mami-Chouaib, F.; Escudier, B.; Chouaib, S. |
Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor |
journalArticle |
2015 |
Joskin, J.; de Baere, T.; Auperin, A.; Tselikas, L.; Guiu, B.; Farouil, G.; Boige, V.; Malka, D.; Leboulleux, S.; Ducreux, M.; Baudin, E.; Deschamps, F. |
Daily versus weekly prostate cancer image-guided radiotherapy: Phase 3 multicenter randomized trial |
journalArticle |
2018 |
de Crevoisier, R.; Bayar, M. A.; Pommier, P.; Muracciole, X.; Pêne, F.; Dudouet, P.; Latorzeff, I.; Beckendorf, V.; Bachaud, J. M.; Laplanche, A.; Supiot, S.; Chauvet, B.; Nguyen, T. D.; Bossi, A.; Créhange, G.; Lagrange, J. L. |
Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial |
journalArticle |
2016 |
Krol, A.; Ferrer, L.; Pignon, J. P.; Proust-Lima, C.; Ducreux, M.; Bouche, O.; Michiels, S.; Rondeau, V. |